ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03301168
Recruitment Status : Recruiting
First Posted : October 4, 2017
Last Update Posted : September 3, 2018
Sponsor:
Information provided by (Responsible Party):
Bellicum Pharmaceuticals

Brief Summary:
This study will evaluate pediatric patients with malignant or non-malignant blood cell disorders who are having a blood stem cell transplant depleted of T cell receptor (TCR) alfa and beta cells that comes from a partially matched family donor. The study will assess whether immune cells, called T cells, from the family donor, that are specially grown in the laboratory and given back to the patient along with the stem cell transplant can help the immune system recover faster after transplant. As a safety measure these T cells have been programmed with a self-destruct switch so that they can be destroyed if they start to react against tissues (graft versus host disease).

Condition or disease Intervention/treatment Phase
Acute Lymphoblastic Leukemia Leukemia, Acute Myeloid (AML), Child Lymphoma, Non-Hodgkin Myelodysplastic Syndromes Primary Immune Deficiency Disorder Osteopetrosis Cytopenia Hemoglobinopathy in Children Anemia, Aplastic Biological: BPX-501 T cells Drug: AP1903 Phase 1 Phase 2

Expanded Access : An investigational treatment associated with this study is available outside the clinical trial.   More info ...

Detailed Description:

This is a Phase 2 extension study evaluating the safety and feasibility of BPX-501 T cells infused after partially mismatched, related, TCR alpha beta T cell depleted hematopoietic stem cell transplant (HSCT) in pediatric patients. The purpose of this clinical trial is to determine whether BPX-501 infusion can enhance immune reconstitution in those patients with hematologic disorders, with the potential for reducing the severity and duration severe acute graft versus host disease (GvHD).

The trial will also evaluate the treatment of GvHD by the infusion of dimerizer drug (AP1903/rimiducid) in those subjects who present with GVHD that does not adequately respond to standard of care therapy.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 120 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Extension Study of CaspaCIDe T Cells (BPX-501) From an HLA-partially Matched Family Donor After Negative Selection of TCR αβ+T Cells in Pediatric Patients Affected by Hematological Disorders
Actual Study Start Date : April 2014
Estimated Primary Completion Date : December 2018
Estimated Study Completion Date : December 2020


Arm Intervention/treatment
Experimental: BPX-501 T cells and AP1903

TCR alpha beta depleted graft infusion with addback of BPX-501 T cells.

AP1903: Dimerizer drug administered to subjects who present with Grade I-IV acute GVHD with inadequate response to steroids within 48 hours of treatment or mild to severe chronic GVHD with inadequate response to steroids within 7 days of treatment.

Biological: BPX-501 T cells
T cells transduced with CaspaCIDe® safety switch

Drug: AP1903
administered to inactivate BPX-501 cells in the event of GVHD
Other Name: rimiducid




Primary Outcome Measures :
  1. non-relapse/transplant related mortality (TRM/NRM) [ Time Frame: 1 year ]
    To maintain the cumulative incidence of non-relapse/transplant related mortality (TRM/NRM) at 1 year in subjects given the MTD defined during the Phase I portion of the study comparable to that of a historical cohort of subjects given the alpha/beta T-cell depleted HSCT without any T-cell add-back (i.e., below 10%)


Secondary Outcome Measures :
  1. Disease-free survival [ Time Frame: 2 years ]
    Disease-free survival rates after transplantation

  2. Relapse [ Time Frame: 1 year ]
    Cumulative incidence of relapse

  3. acute GVHD [ Time Frame: 1 year ]
    Cumulative incidence and severity of acute GVHD

  4. chronic GVHD [ Time Frame: 2 years ]
    Cumulative incidence and severity of chroonic GVHD

  5. Kinetics of donor cell engraftment [ Time Frame: 3 times per week after transplant until the neutrophil count reaches 0.5 x 10E9/L. Thereafter, at least 2 times per week until the neutrophil count is > 1.0 x 10E9/L and platelets > 100 x 10E9/L. ]
    time to hematopoietic recovery defined as: neutrophils > 0.5 x 10E9/L for 3 consecutive days together with platelet count > 20 x 10E9/L and without platelet support for 7 consecutive days



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   1 Month to 26 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age > 1 month and < 26 years
  2. Life expectancy > 10 weeks
  3. Subjects deemed eligible for allogeneic stem cell transplantation.
  4. Subjects with life-threatening hematological malignancies (high-risk ALL in 1st CR, ALL in 2nd or subsequent CR, AML in 1st CR, AML in 2nd or subsequent CR, myelodysplastic syndromes, non-Hodgkin lymphomas in 2nd or subsequent CR, other hematologic malignancies eligible for stem cell transplantation per institutional standard);
  5. Non-malignant disorders amenable to cure by an allograft:

    1. primary immune deficiencies,
    2. severe aplastic anemia not responding to immune suppressive therapy,
    3. osteopetrosis,
    4. hemoglobinopathies, (thalassemias, and sickle cell anemia, and Diamond-Blackfan anemia among others)
    5. congenital/hereditary cytopenia, including Fanconi Anemia before any clonal malignant evolution (MDS, AML) Note: Subjects will be eligible if they meet either item 4 OR item 5.
  6. Lack of suitable conventional donor (HLA identical sibling or HLA phenotypically identical relative or 10/10 unrelated donor evaluated using high resolution molecular typing) or presence of rapidly progressive disease not permitting time to identify an unrelated donor
  7. A minimum genotypic identical match of 5/ 10 is required.
  8. The donor and recipient must be identical, as determined by high resolution typing, at least one allele of each of the following genetic loci: HLA-A, HLA-B, HLA-Cw, HLA- DRB1 and HLA-DQB1.
  9. Lansky/Karnofsky score > 50
  10. Signed written informed consent

Exclusion Criteria:

  1. 1. Greater than Grade II acute GVHD or chronic extensive GVHD due to a previous allograft at the time of inclusion
  2. Subject receiving an immunosuppressive treatment for GVHD treatment due to a previous allograft at the time of inclusion
  3. Dysfunction of liver (ALT/AST > 5 times normal value, or bilirubin > 3 times normal value), or of renal function (creatinine clearance < 30 mL / min)
  4. Severe cardiovascular disease (arrhythmias requiring chronic treatment, congestive heart failure or left ventricular ejection fraction < 40%)
  5. Current active infectious disease (including positive HIV serology or viral RNA)
  6. Serious concurrent uncontrolled medical disorder
  7. Pregnant or breastfeeding subject
  8. For subjects who have received more than 1 x 10E5 alpha/beta T cells/kg with the graft infusion the clinical trial site must contact the sponsor for approval to be eligible to receive BPX-501 infusion.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03301168


Contacts
Contact: Neena Kapoor, MD nkapoor@chla.usc.edu

Locations
United States, California
Children's Hospital Los Angeles Recruiting
Los Angeles, California, United States, 90027
Contact: Renna Killen, RN    323-361-2217    rkillen@chla.usc.edu   
Principal Investigator: Neena Kapoor, MD         
Stanford University; Division of Pediatric Stem Cell Transplant & Regenerative Medicine Recruiting
Palo Alto, California, United States, 94304
Contact: Gopin Saini    650-725-9032    Gopin.Saini@stanford.edu   
Principal Investigator: Alice Bertaina, MD         
United States, District of Columbia
Children's National Medical Center Recruiting
Washington, District of Columbia, United States, 20010
Contact: Divyesh Kukadiya    202-476-6850    Dkukadiy@childrensnational.org   
Principal Investigator: David Jacobsohn, MD, ScM         
United States, Georgia
Children's Healthcare of Atlanta Recruiting
Atlanta, Georgia, United States, 30322
Contact: Ashley Griffin    404-785-0653    ashley.griffin@choa.org   
Principal Investigator: Lakshmanan Krishnamurti, MD         
United States, Massachusetts
Dana-Farber Boston Children's Cancer and Blood Disorders Center Recruiting
Boston, Massachusetts, United States, 02215
Contact: Colleen Dansereau    617-919-7008    colleen.dansereau@childrens.harvard.edu   
Principal Investigator: Susanne Baumeister, MD         
United States, New York
Children's Hospital at Montefiore Recruiting
Bronx, New York, United States, 10467
Contact: Elodie Benard    718-741-2076    ebenard@montefiore.org   
Principal Investigator: Michelle Lee, MD         
United States, Oregon
Oregon Health Sciences University - Doernbecher Children's Hospital Recruiting
Portland, Oregon, United States, 97239
Contact: Jennifer Williamson    503-494-3639    willjenn@ohsu.edu   
Principal Investigator: Eneida Nemecek, MD         
United States, Texas
University of Texas Southwestern-Children's Medical Center Recruiting
Dallas, Texas, United States, 77390
Contact: Gevel Jackson, CCRP    214-456-1430    Gevel.Jackson@childrens.com   
Principal Investigator: Victor M Aquino, MD         
Baylor College of Medicine/ Texas Children's Hospital Recruiting
Houston, Texas, United States, 77030
Contact: Marlen Dinu    832-824-4881    mxdinu@txch.org   
Principal Investigator: Swati Naik, MD         
United States, Washington
Fred Hutchinson Cancer Research Center Recruiting
Seattle, Washington, United States, 98109
Contact: Michelle Bouvier    206-667-6993    meb@fhcrc.org   
Principal Investigator: Lauri M Burroughs, MD         
Sponsors and Collaborators
Bellicum Pharmaceuticals
Investigators
Principal Investigator: Neena Kapoor, MD Children's Hospital of LA

Responsible Party: Bellicum Pharmaceuticals
ClinicalTrials.gov Identifier: NCT03301168     History of Changes
Other Study ID Numbers: BP-U-004
First Posted: October 4, 2017    Key Record Dates
Last Update Posted: September 3, 2018
Last Verified: August 2018

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes

Keywords provided by Bellicum Pharmaceuticals:
ALL
AML
hematologic neoplasms
hematologic malignancies
primary immune deficiences
allogeneic stem cell transplant

Additional relevant MeSH terms:
Leukemia
Myelodysplastic Syndromes
Preleukemia
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia, Lymphoid
Lymphoma, Non-Hodgkin
Immunologic Deficiency Syndromes
Hemoglobinopathies
Osteopetrosis
Anemia, Aplastic
Leukemia, Myeloid, Acute
Leukemia, Myeloid
Neoplasms by Histologic Type
Neoplasms
Bone Marrow Diseases
Hematologic Diseases
Precancerous Conditions
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma
Genetic Diseases, Inborn
Osteosclerosis
Osteochondrodysplasias
Bone Diseases, Developmental
Bone Diseases
Musculoskeletal Diseases
Anemia